EA200500529A1 - КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ПРОТЕИНКИНАЗЫ С-альфа ДЛЯ ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА И СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ - Google Patents

КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ПРОТЕИНКИНАЗЫ С-альфа ДЛЯ ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА И СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ

Info

Publication number
EA200500529A1
EA200500529A1 EA200500529A EA200500529A EA200500529A1 EA 200500529 A1 EA200500529 A1 EA 200500529A1 EA 200500529 A EA200500529 A EA 200500529A EA 200500529 A EA200500529 A EA 200500529A EA 200500529 A1 EA200500529 A1 EA 200500529A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
activity
diabetes mellitus
cardiovascular diseases
proteinkinase
Prior art date
Application number
EA200500529A
Other languages
English (en)
Other versions
EA007926B1 (ru
Inventor
Ян Менне
Херманн Халлер
Original Assignee
Фенос Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фенос Гмбх filed Critical Фенос Гмбх
Publication of EA200500529A1 publication Critical patent/EA200500529A1/ru
Publication of EA007926B1 publication Critical patent/EA007926B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к применению агентов, которые предотвращают экспрессию и/или активность протеинкиназы C-α (PKC-α), в особенности для лечения больных диабетом и осложнений, таких как диабетическая нефропатия, ретинопатия или невропатия.Отчет о международном поиске был опубликован 2004.11.11.(Иммуногистохимическое исследование срезов показывает, что гепарансульфат-протеогликан у контрольных животных с диабетом (B) более не обнаруживается или едва обнаруживается, однако, у мышей PKCαс диабетом (D) образуется в нормальной концентрации)
EA200500529A 2002-09-24 2003-09-23 Композиции для ингибирования протеинкиназы с-альфа для лечения сахарного диабета и сердечно-сосудистых заболеваний EA007926B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10244453A DE10244453A1 (de) 2002-09-24 2002-09-24 Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
PCT/DE2003/003165 WO2004028516A2 (de) 2002-09-24 2003-09-23 Zusammensetzungen zur hemmung der proteinkinase c alpha zur behandlung von diabetes mellitus und kardiovaskulärer erkrankungen

Publications (2)

Publication Number Publication Date
EA200500529A1 true EA200500529A1 (ru) 2005-08-25
EA007926B1 EA007926B1 (ru) 2007-02-27

Family

ID=31969524

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500529A EA007926B1 (ru) 2002-09-24 2003-09-23 Композиции для ингибирования протеинкиназы с-альфа для лечения сахарного диабета и сердечно-сосудистых заболеваний

Country Status (19)

Country Link
US (2) US20050250719A1 (ru)
EP (2) EP1545560B1 (ru)
JP (1) JP2006503841A (ru)
KR (1) KR20050059180A (ru)
CN (1) CN1684694A (ru)
AT (1) ATE475422T1 (ru)
AU (1) AU2003280288B2 (ru)
CA (1) CA2499818A1 (ru)
DE (3) DE10244453A1 (ru)
DK (1) DK1545560T3 (ru)
EA (1) EA007926B1 (ru)
ES (1) ES2356286T3 (ru)
IS (1) IS7777A (ru)
MX (1) MXPA05002930A (ru)
NO (1) NO20051242L (ru)
NZ (1) NZ538857A (ru)
PL (1) PL374829A1 (ru)
UA (1) UA88257C2 (ru)
WO (1) WO2004028516A2 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
US20050066381A1 (en) * 2003-09-19 2005-03-24 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity
WO2005038013A1 (en) * 2003-10-07 2005-04-28 Isis Pharmaceuticals, Inc. Artisense oligonucleotides optimized for kidney targeting
US9144594B2 (en) * 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
WO2007067812A2 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
US20080181877A1 (en) * 2006-03-22 2008-07-31 Leangene Ab, C/O Cit Ekonomiservice Ab Method For Monitoring the Effect of Compounds on Foxc2 Expression
ES2584327T3 (es) 2007-01-31 2016-09-27 Biosuccess Biotech Company Composiciones y métodos de uso de ésteres de forbol
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
JP2013506687A (ja) 2009-09-30 2013-02-28 プレジデント アンド フェロウズ オブ ハーバード カレッジ オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
WO2012063272A1 (en) 2010-11-12 2012-05-18 Gentium S.P.A. Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
NZ628294A (en) 2012-01-18 2017-11-24 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters for the treatment of stroke
WO2013182905A2 (en) * 2012-06-05 2013-12-12 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
TWI750481B (zh) * 2013-01-18 2021-12-21 美商華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
TWI687217B (zh) * 2014-01-10 2020-03-11 華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
BR112016017444A2 (pt) * 2014-01-29 2017-10-10 Inst Nat Sante Rech Med molécula e método
JP6778114B2 (ja) * 2014-04-14 2020-10-28 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． イミド系タンパク質分解モジュレーター及び関連する使用方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10752699B2 (en) 2015-06-29 2020-08-25 Regents Of The University Of Minnesota Anti-APOBEC3 antibodies and methods of making and using
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
JP2020536021A (ja) * 2017-09-29 2020-12-10 セーフワークス エルエルシーＳａｆｅＷｏｒｋｓ， ＬＬＣ 直流電源を備えるホイストシステム
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета
WO2022092884A1 (ko) * 2020-10-29 2022-05-05 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
CA2093008A1 (en) * 1990-10-01 1992-04-02 Charles H. Hennekens Beta-carotene and vitamin e therapy for inhibition of major vascular events
KR920703513A (ko) * 1990-11-02 1992-12-18 클레이턴 아이. 턴칸 단백질 활성효소 c(protein kinase c)를 방해하는 비스-(하이드록시알킬아미노)-안트라퀴논
WO1992017064A2 (en) * 1991-04-08 1992-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of protein kinase c function
PT817627E (pt) 1993-12-23 2005-07-29 Lilly Co Eli Inibidores da proteina cinase c
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
SI0776895T1 (en) * 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
CZ347098A3 (cs) * 1996-05-01 1999-06-16 Eli Lilly And Company Halogenem substituovaná sloučenina jako inhibitor protein kinázy C
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
US20050066381A1 (en) * 2003-09-19 2005-03-24 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity

Also Published As

Publication number Publication date
NZ538857A (en) 2010-10-29
PL374829A1 (en) 2005-10-31
EA007926B1 (ru) 2007-02-27
ES2356286T3 (es) 2011-04-06
KR20050059180A (ko) 2005-06-17
JP2006503841A (ja) 2006-02-02
UA88257C2 (ru) 2009-10-12
DK1545560T3 (da) 2010-11-22
AU2003280288A1 (en) 2004-04-19
EP2338498A1 (de) 2011-06-29
WO2004028516A2 (de) 2004-04-08
WO2004028516A3 (de) 2004-11-11
EP1545560B1 (de) 2010-07-28
MXPA05002930A (es) 2005-09-30
DE10244453A1 (de) 2004-04-01
CN1684694A (zh) 2005-10-19
AU2003280288B2 (en) 2008-08-28
CA2499818A1 (en) 2004-04-08
IS7777A (is) 2005-03-30
EP1545560A2 (de) 2005-06-29
DE50312935D1 (de) 2010-09-09
ATE475422T1 (de) 2010-08-15
US20090191194A1 (en) 2009-07-30
NO20051242L (no) 2005-06-01
DE10393825D2 (de) 2005-08-11
US20050250719A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
EA200500529A1 (ru) КОМПОЗИЦИИ ДЛЯ ИНГИБИРОВАНИЯ ПРОТЕИНКИНАЗЫ С-альфа ДЛЯ ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА И СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ
RS51449B (sr) Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
MXPA04004548A (es) Acidos heteroarilalalcanoicos substituidos y su uso como inhibidores de aldosa reductasa.
DE602004011985D1 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
NO20062292L (no) Fremgangsmate for behandling av transplantasjonsavstoting
PE20040291A1 (es) COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
EP2862859A3 (en) Compounds, compositions and methods
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
EA200501645A1 (ru) Ингибиторы гликогенфосфорилазы, представляющие собой амиды пирролопиридин-2-карбоновых кислот
NO20054743L (no) Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonister
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
DE602005008412D1 (de) Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen
WO2004024093A3 (en) Device and method for treating restenosis
ATE401073T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
BRPI0406455A (pt) Combinação farmacêutica para profilaxia ou terapia de doenças cardiovasculares, cardiopulmonares, pulmonares ou renais
WO2003031407A3 (en) β-LACTAMYL VASOPRESSIN VlaANTAGONISTS
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
SI1587584T1 (sl) Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni
YU40202A (sh) Novi derivati tiazolidindiona kao antidijabetički agensi
ECSP045222A (es) INHIBIDORES DE LA ADHESION CELULAR MEDIADA POR INTEGRINA aLb2
IL163344A (en) 2-(4-(3-cyclopentyloxy-4-difluoromethoxyphenyl)-4-cyanopiperidin-1-yl)acetic acid derivative compounds, process for their synthesis and compositions comprising the compounds as the active ingredient
WO2005058243A3 (en) Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ TM RU